PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	Substitute for form 1449A/PTO			Complete if Known	92	우	
				Application Number	09/471,669	문	<u> </u>
INFC	PRMATI	ON DIS	CLOSURE	Filing Date	December 24, 1999	Ö	::20
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	John P. Anderson	9	C
				Art Unit	1652	70.	- 211
	(use as mai	ny sheets as	necessary)	Examiner Name	Malgorzata A. Walicka	H	ാവ്
Sheet	1	of	6	Attorney Docket Number	015270-006430US	***	3 3
						5	29

		· · · · · · · · · · · · · · · · · · ·	U.S. PATENT DO	OCUMENTS	
		Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Examiner	Cite No. ¹	Number Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
M	1	6,361,975	03-26-2002	Christie, et al.	
illi	2	6,358,725	03-19-2002	Christie, et al.	7
W.	3 .	6,319,489	11-20-2001	Powell, et al.	<u> </u>
JW	4	6,319,689	11-20-2001	Powell, et al.	70
W.	5	6,313,268	11-06-2001	Hook	N. C.
dw	6	6,245,884	06-12-2001	Hook	1 ER
M	7	6,245,964	06-12-2001	McConlogue, et al.	
Jul.	8	6,221,645	04-24-2001	Chrysler, et al.	80002 000/2
W	9	6,211,428	04-03-2001	Singh, et al.	-Jm 892.
M	-10	6,162,630	12-19-2000	Powell, et al.	-m 8928
dw	11	6,025,180	02-15-2000	Powell, et al.	
dW	12	5,942,400	08-24-1999	Anderson, et al.	- alterry in 892
W,	13	5,877,015	03-02-1999	Hardy, et al.	
W	14	5,849,560	12-15-1998	Abraham	
W.	15	5,837,672	11-17-1998	Schenk, et al.	
W	16	5,795,963	08-18-1998	Mullan	
W	17	5,766,846	06-16-1998	Schlossmacher, et al.	
IW	18	5,750,349	05-12-1998	Suzuki, et al.	
W	-19-	5,744,346	04-28-1998	Chrysler, et al.	In 892
iM.	20	5,733,768	03-31-1998	Dixon, et al.	
Mil	21	5,593,846	01-14-1997	Schenk, et al.	
W:	22	5,455,169	10-03-1995	Mullan	
iW.	23	5,424,205	06-13-1995	Dovey, et al.	
W,	112	09/869,414		Gurney, et al.	
W	90	09/794,927		Gurney, et al.	
(MV)	91	09/794,925		Gurney, et al.	

				
Examiner Signature	Montrolle	Date Considered	12/17/02	
0.9	I VIN UN WWW			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

PA 3269588 v1

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document with the document of the patent document with the document of the patent of the patent document. ⁵ Kind Office and ST. 40 if specific the document of the patent document of the patent document of the patent document of the patent document. ⁵ Kind Office and ST. 40 if specific the document of the patent document of the patent document. ⁵ Kind Office and ST. 40 if specific the document of the patent document of the patent document. ⁵ Kind Office and ST. 40 if specific the document of the patent document of the patent document. ⁵ Kind Office and ST. 40 if specific the patent document of the patent document. ⁵ Kind Office and ST. 40 if specific the patent document of the patent document of the patent document. ⁵ Kind Office and ST. 40 if specific the patent document of the patent docu under WIPO Standard ST. 16 if possible. 9 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for form 1449A/PTO			Complete if Known			
				Application Number	09/471,669		
INFO	RMATION	DIS	CLOSURE	Filing Date	December 24, 1999		
STAT	TEMENT BY	Y AI	PPLICANT	First Named Inventor	John P. Anderson		
			•	Art Unit	1652		
	(use as many shee	ets as	necessary)	Examiner Name	Malgorzata A. Walicka		
Sheet	2	of	6	Attorney Docket Number	015270-006430US		

U.S. PATENT DOCUMENTS										
Examiner	Cite No.1	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear					
iW.	89	09/795,847	NA	Gurney, et al.						
cW	92	09/794,748		Gurney, et al.						
iW.	88	09/794,743		Gurney, et al.						
W	111	09/681,442		Gurney, et al.						
ilW	87	09/551,853		Gurney, et al.	CP CP					
illy	96	09/548,376		Gurney, et al.						
W.	24	09/548,373		Gurney, et al.	9 6					
W	99	09/548,372		Gurney, et al.	<u> </u>					
ille	94	09/548,370		Gurney, et al.						
W.	97	09/548,369		Gurney, et al.	2002					
iW.	100	09/548,368		Gurney, et al.	1600/2900					
iW	98	09/548,367		Gurney, et al.	8					
CM	25	09/548,366		Gurney, et al.						
ilw,	95	09/548,365		Gurney, et al						
W,	26	09/416,901		Gurney, et al.						
W	27	09/404,133		Gurney, et al.						
W.	28	09/277,229		Citron, et al.						
iM	29	60/210,292		Hong, et al.						
WV.	30	60/178,368		Lin, et al.						
W	31	60/177,836		Lin, et al.						
W	32	60/168,060		Lin, et al.						
W	33	60/155,493		Gurney, et al.						
·W	34	60/141,363		Lin, et al.						
MY	35	60/139,172		Anderson, et al.						
ihr	36	60/119,571		Basi, et al.						
im	37	60/114,408		Basi, et al.						
M	38	60/101,594		Gurney, et al.						

Examiner Signature	Moralleles	Date Considered	12/17	102	
-----------------------	------------	--------------------	-------	-----	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PA 3269588 v1

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	e for form 1449A/PTO)		Complete if Known			
				Application Number	09/471,669		
INFC	RMATION	DIS	CLOSURE	Filing Date	December 24, 1999		
STA'	TEMENT B'	YA	PPLICANT	First Named Inventor	John P. Anderson		
				Art Unit	1652		
	(use as many she	ets as	necessary)	Examiner Name	Malgorzata A. Walicka		
Sheet	3	of	6	Attorney Docket Number	015270-006430US		

	·				NT DOCUMENTS	S		
Examiner Initials*	Cite No. ¹	Country Code ³	Foreign Patent Documen Number ⁴	Kind Code ^s (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
dW.	-39-	EP	EP 0 855 444	<u></u>	-07-29-1998		already in 832	_
W	40	EP	EP 0 848 062	A2	06-17-1998		0	
W.	48	PCT	WO 01/38487	A2	05-31-2001			
dw.	49	PCT	WO 01/36600	A1	05-25-2001) <u>F</u> C	
ilw	50	PCT	WO 01/31054	A1	05-03-2001		I	丑
clw	51	PCT	WO 01/29563	A1	04-26-2001		8 8	四
und	52	PCT	WO 01/00665	. A2	01-04-2001		1	H
ilw	53	PCT	WO 01/00663	A2	01-04-2001		70	
W.	47	PCT	WO 00/69262	A1	11-23-2000	_	50	\leq
W	46	PCT	WO 00/68266	A1	11-16-2000		1600/2900	Ш
W.	45	PCT	WO 00/58479	A1	10-05-2000		8	U
uW	44	PCT	WO 00/56871	A2	09-28-2000			
iW	43	PCT	WO 00/47618	A3	08-17-2000			
W	-42	PCT	WO 00/23576	A2	04-27-2000		alterdy in 832	
.W	41	PCT	WO 00/17369	A2	03-30-2000		J	
iW.	54	PCT	WO 99/64587	A1	12-16-1999			
W	55	PCT	WO 99/46281	A2	09-16-1999			
M	57	PCT	WO 99/34004	A2	08-07-1999			
JW.	59	PCT	WO 99/31236	A2	06-24-1999			
iW	60	PCT	WO 98/26059		06-18-1998			
W	61	PCT	WO 98/21589		05-22-1998			
ch	62	PCT	WO 98/13488		04-02-1998			
ilw	63	PCT	WO 98/11236		03-19-1998			
M	103	PCT	WO 97/47314		12-18-1997			
elle	56	PCT	WO 96/40885	A2	12-19-1996			
iM	58	PCT	WO 96/31122	A1	10-10-1996			
M	102	PCT	WO 96/20725	A2	07-11-1996			
Examiner Signature		Moder	liclea		Date Considered	12/1	7/02	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

PTO/SB/08B (10-01) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO Complete if Known **Application Number** 09/471,669 INFORMATION DISCLOSURE **Filing Date** December 24, 1999 STATEMENT BY APPLICANT John P. Anderson **First Named Inventor** Art Unit 1652 (use as many sheets as necessary) Malgorzata A. Walicka **Examiner Name** 015270-006430US

Attorney Docket Number

	,	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
M	104	Baldwin, et al., Crystal structures of native and inhibited forms of human cathepsin D: Implications for lysosomal targeting and drug design, <i>PNAS USA</i> , 90:6796-6800 (1993).	
W	105	Brown, et al., Evaluation of Cathepsins D and G and EC 3.4.24.15 as Candidate β-Secretase Proteases Using Peptide and Amyloid Precursor Protein Substrates, <i>Journal of Neurochemistry</i> , 66: 2436-2445 (1996).	
W	106	Chevallier, et al., Cathepsin D displays in vitro β -secretase-like specificity, <i>Brain Research</i> , 750:11-19 (1997).	
W	64	Chyung, et al. Novel β -Secretase Cleavage of β -Amyloid Precursor Protein in the Endoplasmic Reticulum/Intermediate Compartment of NT2N Cells, <i>Journal of Cell Biology</i> , 138: 671-680 (August 11, 1997).	
W	107	Diedrich, et al., Nucleotide sequence of a cDNA encoding mouse cathepsin D, Nucleic Acids Research, 18:7184 (1990).	
dW	65	Elan Corporation, plc and Pharmacia Corporation announce research collaboration, News 08/09/2000, www.elancorp.com.	
W	66	Evin, et al., Alzheimer's disease amyloid precursor protein (βAPP): proteolytic processing, secretases and βA4 amyloid production, <i>Amyloid; Int. J. Exp. Clin. Invest.</i> 1: 263-280 (September 8, 1994).	
M	67	Haass, et al., Amyloid β-peptide is Produced by Cultured Cells During Normal Metabolism, <i>Nature</i> , 359: 322-325 (September 24, 1992).	
W	68	Haass, et al., The Swedish Mutation Causes Early-Onset Alzheimer's Disease by β-Secretase Cleavage Within the Secretory Pathway, <i>Nature Medicine</i> , 12: 1291-1296 (December 1995).	
M	69	Haass, et al., β-Amyloid Peptide and 3-kDa Fragment are Derived by Distinct Cellular Mechanisms, <i>Journal of Biochemistry</i> , 268: 3021-3024 (February 15, 1993).	
M	70	Hirosawa, et al., Characterization of cDNA Clones Selected by the GeneMark Analysis from Size-Fractionated cDNA Libraries From Human Brain, <i>DNA Res.</i> , 6(5): 329-336 (October 29, 1999).	

Examiner Signature Date Consid	lered 12 [17	02
--------------------------------	--------------	----

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3269588 v1



Sheet

of 6

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to respond to a collection of information unless it contains a mile of the collection of information unless it contains a mile of the collection of th

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO Complete if Known **Application Number** 09/471,669 INFORMATION DISCLOSURE Filing Date December 24, 1999 STATEMENT BY APPLICANT **First Named Inventor** John P. Anderson 1652 Art Unit (use as many sheets as necessary) **Examiner Name** Malgorzata A. Walicka 015270-006430US Sheet of Attorney Docket Number

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
M	71	Hussain, et al., Identification of a Novel Aspartic Protease (Asp-2) as β-Secretase, Molecular and Cellular Neuroseience, 14: 419-427 (1999).	892
M	72	Kang, et al., The Precursor of Alzheimer's Disease Amyloid A4 Protein Resembles a Cell-Surface Receptor, <i>Nature</i> , 325: 733-736 (February 19, 1987).	
dw	73	Kitaguchi, et al., Novel Precursor of Alzheimer's Disease Amyloid Protein Shows Protease Inhibitory Activity, <i>Nature</i> , 331: 530-532 (February 11, 1988).	
dw	74	-Knops, et al., Cell-type and Amyloid Precursor Protein-type Specific Inhibition of Aβ Release by Bafilomycin A1, a Selective Inhibitor of Vacuolar ATPases, <i>Journal of Biological Chemistry</i> , 270: 2419-2422 (February 10, 1995).	
W	75	Koo and Squazzo, Evidence that Production and Release of Amyloid β-Protein Involves the Endocytic Pathway, <i>Journal of Biological Chemistry</i> , 269: 17386-17389 (July 1, 1994).	
W	108	Majer, et al., Structure-based subsite specificity mapping of human cathepsin D using statine-based inhibitors, <i>Protein Science</i> , 6:1458-1466 (1997).	
M	76	Mullan, et al., A Pathogenic Mutation for Probable Alzheimer's Disease in the APP Gene at the N-Terminus of β -Amyloid, <i>Nature Genetics</i> 1: 345-347, (August 1992).	
JW	77	PCT Search report for PCT/US99/20881	
M	78	PCT Search report for PCT/US00/03819	
W	79	Ponte, et al., A New A4 Amyloid mRNA Contains a Domain Homologous to Serine Proteinase Inhibitors, <i>Nature</i> , 331: 525-527 (February 11, 1988).	
W	109	Saftig, et al., Amyloidogenic Processing of Human Amyloid Precursor Protein in Hippocampal Neurons Devoid of Cathepsin D, <i>Journal of Biological Chemistry</i> , 271:27241-27244 (1996).	
W	110	Schechter, et al., On the size of the active site in proteases. I. Papain, Biochemical and Biophysical Research Communications, 27:157-162 (1967).	

	, ,			7	
Examiner Signature	Malvele	Date Considered	12	117/	02
(- 3					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

RECEIVED DEC 1 0 2002

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO				Complete if Known		
1815	ODMATI	2N DIG	OLOCUDE	Application Number	09/471,669	
			CLOSURE	Filing Date	December 24, 1999	
STATEMENT BY APPLICANT				First Named Inventor	John P. Anderson	\subseteq
				Art Unit	1652	Z
(use as many sheets as necessary)			necessary)	Examiner Name	Malgorzata A. Walicka	רד
Sheet	t 6	of	6	Attorney Docket Number	015270-006430US	

			— ČŠ
		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	_ <u>Š</u>
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
dul	80	Seubert, et al. Secretion of β -amyloid Precursor Protein Cleaved at the Amino Terminus of the β -amyloid Peptide, <i>Nature</i> , 361: 260-263 (January 21, 1993).	
der	81	Sinha, et al., Purification and Cloning of Amyloid Precursor Pretein β-Secretase from Human Brain, Nature, 402: 537-540 (December, 2 1999).	892
M	82	Szecsi, The Aspartic Proteases, Scand. J. Clin. Lab. Invest., 52 (suppl. 210): 5-22 (1992).	
M	83	Tanzi, et al., Protease Inhibitor Domain Encoded by an Amyloid Protein Precursor mRNA Associated with Alzheimer's Disease, <i>Nature</i> , 331: 528-530 (February 11, 1988).	
dW	93	Thompson, et al., Expression and characterization of human β -secretase candidates metalloendopeptidase MP78 and cathepsin D in β APP-overexpressing cells, <i>Molecular Brain Research</i> , 48:206-214.	
M	84	Vasse, et al., β-secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE, Science, 286 (5440): 735-41 (October 22, 1999).	
M	85	Yan, et al., Membrane-anchored Aspartyl Protease with Alzheimer's Disease β -Secretase Activity, Nature, 402: 533-537 (December 2, 1999).	
M	101	Young, et al., HIV-1 Protease Inhibitors Based on Hydroxyethylene Dipeptide Isosteres: An Investigation into the Role of the P ₁ -Side Chain on Structure-Activity, <i>J. Med. Chem.</i> , 35:1702-1709 (1992).	
M	86	Zhao, et al., β -Secretase Processing of the β -Amyloid Precursor Protein in Transgenic Mice Is Efficient in Neurons but Inefficient in Astrocytes, <i>Journal of Biological Chemistry</i> , 271: 31407-31411 (December 6, 1996).	

Examiner Signature	Malieka	Date Considered	12/17/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

in 882

892 E.R.

892

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.